Home > Publications Database > Characteristics of subjective cognitive decline associated with amyloid positivity. > print

001     163604
005     20230915090527.0
024 7 _ |a pmc:PMC9786747
|2 pmc
024 7 _ |a 10.1002/alz.12512
|2 doi
024 7 _ |a pmid:34877782
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:118400231
|2 altmetric
037 _ _ |a DZNE-2022-00350
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Janssen, Olin
|b 0
245 _ _ |a Characteristics of subjective cognitive decline associated with amyloid positivity.
260 _ _ |a Hoboken, NJ
|c 2022
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1690535669_3221
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY-NC)
520 _ _ |a The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited.In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity.Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages.Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a amyloid
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a positron emission tomography
|2 Other
650 _ 7 |a subjective cognitive decline
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyloid
|2 MeSH
650 _ 2 |a Amyloidogenic Proteins
|2 MeSH
650 _ 2 |a Amyloidosis
|2 MeSH
650 _ 2 |a Apolipoprotein E4: genetics
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Jansen, Willemijn J
|b 1
700 1 _ |a Vos, Stephanie J B
|b 2
700 1 _ |a Boada, Merce
|b 3
700 1 _ |a Parnetti, Lucilla
|b 4
700 1 _ |a Gabryelewicz, Tomasz
|b 5
700 1 _ |a Fladby, Tormod
|b 6
700 1 _ |a Molinuevo, José Luis
|b 7
700 1 _ |a Villeneuve, Sylvia
|b 8
700 1 _ |a Hort, Jakub
|b 9
700 1 _ |a Epelbaum, Stéphane
|b 10
700 1 _ |a Lleó, Alberto
|b 11
700 1 _ |a Engelborghs, Sebastiaan
|b 12
700 1 _ |a van der Flier, Wiesje M
|b 13
700 1 _ |a Landau, Susan
|b 14
700 1 _ |a Popp, Julius
|b 15
700 1 _ |a Wallin, Anders
|b 16
700 1 _ |a Scheltens, Philip
|b 17
700 1 _ |a Rikkert, Marcel Olde
|b 18
700 1 _ |a Snyder, Peter J
|b 19
700 1 _ |a Rowe, Chris
|b 20
700 1 _ |a Chételat, Gaël
|b 21
700 1 _ |a Ruíz, Agustin
|b 22
700 1 _ |a Marquié, Marta
|b 23
700 1 _ |a Chipi, Elena
|b 24
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 25
|u dzne
700 1 _ |a Heneka, Michael
|0 P:(DE-2719)2000008
|b 26
|u dzne
700 1 _ |a Boecker, Henning
|0 P:(DE-2719)2810726
|b 27
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 28
|u dzne
700 1 _ |a Jarholm, Jonas
|b 29
700 1 _ |a Rami, Lorena
|b 30
700 1 _ |a Tort-Merino, Adrià
|b 31
700 1 _ |a Binette, Alexa Pichet
|b 32
700 1 _ |a Poirier, Judes
|b 33
700 1 _ |a Rosa-Neto, Pedro
|b 34
700 1 _ |a Cerman, Jiri
|b 35
700 1 _ |a Dubois, Bruno
|b 36
700 1 _ |a Teichmann, Marc
|b 37
700 1 _ |a Alcolea, Daniel
|b 38
700 1 _ |a Fortea, Juan
|b 39
700 1 _ |a Sánchez-Saudinós, M Belén
|b 40
700 1 _ |a Ebenau, Jarith
|b 41
700 1 _ |a Pocnet, Cornelia
|b 42
700 1 _ |a Eckerström, Marie
|b 43
700 1 _ |a Thompson, Louisa
|b 44
700 1 _ |a Villemagne, Victor
|b 45
700 1 _ |a Buckley, Rachel
|b 46
700 1 _ |a Burnham, Samantha
|b 47
700 1 _ |a Delarue, Marion
|b 48
700 1 _ |a Freund-Levi, Yvonne
|b 49
700 1 _ |a Wallin, Åsa K
|b 50
700 1 _ |a Ramakers, Inez
|b 51
700 1 _ |a Tsolaki, Magda
|b 52
700 1 _ |a Soininen, Hilkka
|b 53
700 1 _ |a Hampel, Harald
|b 54
700 1 _ |a Spiru, Luiza
|b 55
700 1 _ |a Initiative, Alzheimer's Disease Neuroimaging
|b 56
|e Collaboration Author
700 1 _ |a group, FACEHBI study
|b 57
|e Collaboration Author
700 1 _ |a group, PREVENT-AD research
|b 58
|e Collaboration Author
700 1 _ |a Tijms, Betty
|b 59
700 1 _ |a Ossenkoppele, Rik
|b 60
700 1 _ |a Verhey, Frans R J
|b 61
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 62
|u dzne
700 1 _ |a Visser, Pieter Jelle
|b 63
773 _ _ |a 10.1002/alz.12512
|g p. alz.12512
|0 PERI:(DE-600)2201940-6
|n 10
|p 1832-1845
|t Alzheimer's and dementia
|v 18
|y 2022
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/163604/files/DZNE-2022-00350.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/163604/files/DZNE-2022-00350.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:163604
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2810544
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 26
|6 P:(DE-2719)2000008
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 27
|6 P:(DE-2719)2810726
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 28
|6 P:(DE-2719)2811024
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 62
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b ALZHEIMERS DEMENT : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 1
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)5000034
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21